According to the company, candidate drug GLPG1790 is a selective and potent inhibitor of a novel breast cancer target. It has proven to be highly active against triple-negative breast cancer in a mouse xenograft model where it completely blocked tumour growth.
According to the terms of the collaboration, Ablynx will provide access to Nanobodies against a particular, undisclosed cancer target and Spirogen will offer access to its proprietary cytotoxic warheads and conjugation technologies.
As per the terms of the partnership, Ablynx will provide access to novel nanobodies against a specific, undisclosed cancer target, and Spirogen will provide access to its proprietary cytotoxic warheads (PBDs) and conjugation technologies.
According to the company, NBE-002 is a best-in-class immune-stimulatory ADC (iADC) treatment against the ROR1 cancer target and is planned to enter into clinical trials in mid 2020 in triple negative breast cancer and other indications.
Some 20,137 patients in England have had to wait longer than two months to start treatment - a key NHS cancer target - following an urgent referral to hospital by their GP, figures for 2015/16 to date show.